Parastoo B Dahi, Sheila Kenny, Jessica Flynn, Sean M Devlin, Josel D Ruiz, Stephanie A Chinapen, Oscar B Lahoud, Matthew J Matasar, Craig H Moskowitz, Miguel-Angel Perales, Gunjan Shah, Craig S Sauter, Sergio A Giralt, Alexander I Geyer, Ann A Jakubowski
This study aims to evaluate the predictive value of routine pulmonary function testing (PFT) at the 12-month mark post-autologous hematopoietic cell transplant (AHCT) in identifying clinically significant lung disease in lymphoma survivors. In 247 patients, 173 (70%) received BEAM (carmustine, etoposide, cytarabine, melphalan), and 49 (20%) received TBC (thiotepa, busulfan, cyclophosphamide) conditioning regimens. Abnormal baseline PFT was noted in 149 patients (60%). Thirty-four patients had a significant decline (reduction of >/= 20% in DLCO or FEV1 or FVC) in post-AHCT PFT, with the highest incidence in the CNS lymphoma group (39%)...
September 10, 2023: Leukemia & Lymphoma